AL-102 is a small molecule commercialized by Ayala Pharmaceuticals, with a leading Phase III program in Benign Tumor. According to Globaldata, it is involved in 4 clinical trials, of which 2 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of AL-102’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AL-102 is expected to reach an annual total of $88 mn by 2032 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BMS-986115 (AL-102) is under development for the treatment of desmoid tumors, relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and relapsed/refractory multiple myeloma. It is administered orally. The drug candidate is a pan-notch gamma secretase inhibitor.
It was under development for the treatment of advanced solid tumors
Ayala Pharmaceuticals Overview
Ayala Pharmaceuticals Inc (Ayala Pharmaceuticals) is a clinical-stage bio-pharmaceutical company which develops novel drugs for defined cancers. Its lead product candidate AL101 and AL102 to treat cancers. The products render different cancers like desmoid tumors, adenoid cystic carcinoma (ACC), triple negative breast cancer (TNBC) and T-cell acute lymphoblastic leukemia (T-ALL). Ayala Pharmaceuticals desmoid tumors arise in upper and lower extremities, abdominal wall, head and neck area, mesenteric root and chest wall of the body. In addition, it also focuses on inhibiting the Notch activating pathway with best-in-class gamma secretase inhibitors (GSIs). The company has operations in Israel and the US. Ayala Pharmaceuticals is headquartered in Wilmington, Delaware, the US.
For a complete picture of AL-102’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.